» Articles » PMID: 36143150

Pathogenesis and Personalized Interventions for Pharmacological Treatment-Resistant Neuropsychiatric Symptoms in Alzheimer's Disease

Overview
Journal J Pers Med
Date 2022 Sep 23
PMID 36143150
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is the most common form of dementia, with cognitive impairment as a core symptom. Neuropsychiatric symptoms (NPSs) also occur as non-cognitive symptoms during the disease course, worsening the prognosis. Recent treatment guidelines for NPSs have recommended non-pharmacological treatments as the first line of therapy, followed by pharmacological treatments. However, pharmacological treatment for urgent NPSs can be difficult because of a lack of efficacy or an intolerance, requiring multiple changes in psychotropic prescriptions. One biological factor that might be partly responsible for this difficulty is structural deterioration in elderly people with dementia, which may cause a functional vulnerability affecting the pharmacological response. Other causative factors might include awkward psychosocial interpersonal relations between patients and their caregiver, resulting in distressful vicious circles. Overlapping NPS sub-symptoms can also blur the prioritization of targeted symptoms. Furthermore, consistent neurocognitive reductions cause a primary apathy state and a secondary distorted ideation or perception of present objects, leading to reactions that cannot be treated pharmacologically. The present review defines treatment-resistant NPSs in AD; it may be necessary and helpful for clinicians to discuss the pathogenesis and comprehensive solutions based on three major hypothetical pathophysiological viewpoints: (1) biology, (2) psychosociology, and (3) neurocognition.

Citing Articles

Assessing behavioral and psychological symptoms of dementia: a comprehensive review of current options and future perspectives.

Pozzi F, Cali L, Ferrarese C, Appollonio I, Tremolizzo L Front Dement. 2024; 2:1226060.

PMID: 39082001 PMC: 11285590. DOI: 10.3389/frdem.2023.1226060.


BPSDiary study protocol: a multi-center randomized controlled trial to compare the efficacy of a BPSD diary vs. standard care in reducing caregiver's burden.

Pozzi F, Cali L, DAntonio F, Altomare A, Sepe Monti M, Panigutti M Front Dement. 2024; 2:1301280.

PMID: 39081982 PMC: 11285609. DOI: 10.3389/frdem.2023.1301280.


Cognition Mediates the Association Between Cerebrospinal Fluid Biomarkers of Amyloid and P-Tau and Neuropsychiatric Symptoms.

Frank B, Walsh M, Hurley L, Groh J, Blennow K, Zetterberg H J Alzheimers Dis. 2024; 100(3):1055-1073.

PMID: 38995786 PMC: 11805585. DOI: 10.3233/JAD-240125.

References
1.
Nagata T, Shinagawa S, Kobayashi N, Kondo K, Shigeta M . A case of V180I genetic mutation Creutzfeldt Jakob disease (CJD) with delusional misidentification as an initial symptom. Prion. 2021; 16(1):7-13. PMC: 9757407. DOI: 10.1080/19336896.2021.2017701. View

2.
Mustapic M, Presecki P, Pivac N, Mimica N, Hof P, Simic G . Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 44:94-9. PMC: 3952071. DOI: 10.1016/j.pnpbp.2013.02.002. View

3.
Sartori G, Snitz B, Sorcinelli L, Daum I . Remote memory in advanced Alzheimer's disease. Arch Clin Neuropsychol. 2004; 19(6):779-89. DOI: 10.1016/j.acn.2003.09.007. View

4.
Ruthirakuhan M, Herrmann N, Abraham E, Chan S, Lanctot K . Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev. 2018; 5:CD012197. PMC: 6494556. DOI: 10.1002/14651858.CD012197.pub2. View

5.
Graff-Guerrero A, Rajji T, Mulsant B, Nakajima S, Caravaggio F, Suzuki T . Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study. JAMA Psychiatry. 2015; 72(9):927-34. DOI: 10.1001/jamapsychiatry.2015.0891. View